Matchpoint Therapeutics partners with Novartis to develop oral covalent inhibitors for inflammatory diseases, with potential ...

(Reuters) -Swiss drugmaker Novartis will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs ...

Novartis is serving up $60 million to partner with Matchpoint Therapeutics in hopes of getting an oral covalent inhibitor ...

Swiss pharma major Novartis (NOVN: VX) has entered into an exclusive option and license deal with Matchpoint Therapeutics to ...

Novartis and Matchpoint Therapeutics have entered into a partnership worth $1bn to develop oral inhibitors for inflammatory ...

Matchpoint Therapeutics has entered into an exclusive option and license agreement with Novartis to develop and commercialize oral covalent inhibitors.

Matchpoint Therapeutics Inc. and Novartis AG have entered into an exclusive option and license agreement to develop and commercialize oral covalent inhibitors targeting a transcription factor linked ...

Matchpoint Therapeutics, a biotechnology company founded to leverage the power of covalency for the discovery of precision small molecule medicines, launched ...

Now, a new company—Matchpoint Therapeutics—is hoping to leverage the power of covalency for the discovery of precision small molecule medicines. The company launched today with $100 million in ...

Matchpoint Therapeutics Inc. has launched with $100 million in financing to research drugs based on covalent chemistry targeting inflammatory diseases, aiming to offer more patient-friendly oral ...

Matchpoint Therapeutics has publicly launched with $70 million in series A financing and an earlier $30 million in seed money to develop covalent drugs for immune diseases.